Subscribe
patent-istock-579425600-duncan-andison
Duncan_Andison / iStockphoto.com
23 January 2019Biotechnology

EPO invalidates Pacific Biosciences patent in Oxford Nanopore dispute

The European Patent Office (EPO) has revoked a patent held by a US biotechnology company, Pacific Biosciences, after its UK-based rival Oxford Nanopore Technologies challenged the validity of the patent.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Oxford Nanopore secures Fed Circ victory in PacBio DNA suit
13 May 2021   The US Court of Appeals for the Federal Circuit has upheld a district court jury decision that found Pacific Biosciences’ DNA sequencing patents—which it had asserted against Oxford Nanopore Technologies—were invalid.
Americas
Pacific Biosciences and Oxford Nanopore settle patent claims
9 May 2018   US-based Pacific Biosciences has entered into a five-year settlement agreement with Oxford Nanopore after the companies were locked in a legal battle.


Editor's picks

UKIPO rejects Boehringer’s SPC for horse inhaler
Europe
UKIPO rejects Boehringer’s SPC for horse inhaler
8 July 2025

Editor's picks

Europe
UKIPO rejects Boehringer’s SPC for horse inhaler
8 July 2025
Americas
Bankruptcy judge approves $305m sale of genetics testing company
1 July 2025
Americas
A step too far? Why Stewart’s approach is dividing opinion
24 June 2025
Europe
Diverging in the detail: UPC local divisions and Court of Appeal take different paths
19 June 2025
Europe
UPC confirms permanent injunction against Curio in 10x tech dispute
17 June 2025
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025

More on this story

Big Pharma
Oxford Nanopore secures Fed Circ victory in PacBio DNA suit
13 May 2021   The US Court of Appeals for the Federal Circuit has upheld a district court jury decision that found Pacific Biosciences’ DNA sequencing patents—which it had asserted against Oxford Nanopore Technologies—were invalid.
Americas
Pacific Biosciences and Oxford Nanopore settle patent claims
9 May 2018   US-based Pacific Biosciences has entered into a five-year settlement agreement with Oxford Nanopore after the companies were locked in a legal battle.

More on this story

Big Pharma
Oxford Nanopore secures Fed Circ victory in PacBio DNA suit
13 May 2021   The US Court of Appeals for the Federal Circuit has upheld a district court jury decision that found Pacific Biosciences’ DNA sequencing patents—which it had asserted against Oxford Nanopore Technologies—were invalid.
Americas
Pacific Biosciences and Oxford Nanopore settle patent claims
9 May 2018   US-based Pacific Biosciences has entered into a five-year settlement agreement with Oxford Nanopore after the companies were locked in a legal battle.

More features

Chicago firm Much Shelist adds partner with ‘entrepreneurial mindset’
Powell Gilbert launches Düsseldorf office with leading patent litigator
Startups toolkit: Why investors want more than patents
J&J fends off generic schizophrenia drug bids
Kilpatrick adds ‘seasoned litigator’ as trademark partner
WATCH: An update on EPO Board of Appeal strategy for 2025 and beyond
Startup challenges rival over brain monitoring tech at ITC
UKIPO rejects Boehringer’s SPC for horse inhaler